Delayed first injection of the once-a-month injectable contraceptive containing 25 mg of medroxyprogesterone acetate and 5 mg of E 2 -cypionate: effects on ovarian function

Author： Petta C.A.   Hays M.   Brache V.   Massai R.   Hua Y.   Alvarez-Sanchez F.   Croxatto H.   d'Arcangues C.   Cook L.A.   Bahamondes L.  

Publisher： Elsevier

ISSN： 0015-0282

Source： Fertility and Sterility, Vol.75, Iss.4, 2001-04, pp. : 744-748

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections

By Canto de Cetina T.E.   Luna M.O.   Cetina Canto J.A.   Bassol S.  

Contraception, Vol. 69, Iss. 2, 2004-02 ,pp. : 115-119

Elsevier

Access to resources Recommend Favorite

Endometrial histology in long-term users of the once-a-month injectable contraceptive Cyclofem

By Bahamondes L.  

Advances in Contraception, Vol. 15, Iss. 1, 1999-03 ,pp. : 1-7

Springer Publishing Company

Access to resources Recommend Favorite

Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function

By Ågren Ulla M.   Anttila Marjatta   Mäenpää-Liukko Kristiina   Rantala Maija-Liisa   Rautiainen Hilkka   Sommer Werner F.   Mommers Ellen  

The European Journal of Contraception and Reproductive Health Care, Vol. 16, Iss. 6, 2011-12 ,pp. : 458-467

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis

By Ilter E.   Karalok H.   Tufekci E. C.   Batur O.  

Climacteric, Vol. 9, Iss. 2, 2006-04 ,pp. : 129-134

Informa Healthcare

Access to resources Recommend Favorite

A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 μg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight

By Endrikat Jan   Sandri Mirella   Gerlinger Christoph   Rübig Alexander   Schmidt Werner   Fortier Michel  

The European Journal of Contraception and Reproductive Health Care, Vol. 12, Iss. 3, 2007-01 ,pp. : 220-228

Informa Healthcare

Access to resources Recommend Favorite